Quick Answer
Arcturus Therapeutics Holdings Inc. reported Cash and Equivalents of $230.91 million for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $230.91M | -2.6% |
| 2024 | $237.03M | -18.8% |
| 2023 | $292.00M | -25.5% |
| 2022 | $391.88M | +5.8% |
| 2021 | $370.49M | -20.0% |
| 2020 | $462.89M | +548.7% |
| 2019 | $71.35M | +94.4% |
| 2018 | $36.71M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $180.36M | -24.0% | -8.2% |
| June 30, 2025 | $196.47M | -24.5% | -9.4% |
| March 31, 2025 | $216.95M | -24.8% | -8.5% |
| December 31, 2024 | $237.03M | -18.8% | -0.1% |
| September 30, 2024 | $237.18M | -24.0% | -8.9% |
| June 30, 2024 | $260.33M | -19.5% | -9.7% |
| March 31, 2024 | $288.40M | -12.1% | -1.2% |
| December 31, 2023 | $292.00M | -25.5% | -6.4% |
- Arcturus Therapeutics Holdings Inc. showed a decrease of -2.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Arcturus Therapeutics Holdings Inc.’s cash and equivalents has grown by 529.0% (from $36.71 million to $230.91 million).
- The most recent figure is from Arcturus Therapeutics Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: